Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Other Non-Current Assets (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Other Non-Current Assets for 6 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 60.15% to $2.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Dec 2025, down 60.15% year-over-year, with the annual reading at $2.2 million for FY2025, 60.15% down from the prior year.
  • Other Non-Current Assets for Q4 2025 was $2.2 million at Caribou Biosciences, down from $3.8 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $5.5 million in Q4 2024, with the low at $810000.0 in Q3 2021.
  • Average Other Non-Current Assets over 5 years is $2.4 million, with a median of $1.6 million recorded in 2023.
  • The sharpest move saw Other Non-Current Assets crashed 61.63% in 2022, then surged 248.11% in 2024.
  • Over 5 years, Other Non-Current Assets stood at $975000.0 in 2021, then surged by 57.74% to $1.5 million in 2022, then rose by 3.12% to $1.6 million in 2023, then soared by 248.11% to $5.5 million in 2024, then crashed by 60.15% to $2.2 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $2.2 million, $3.8 million, and $3.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.